First Horizon Advisors Inc. Buys 293 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

First Horizon Advisors Inc. lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 24.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,491 shares of the biopharmaceutical company’s stock after acquiring an additional 293 shares during the period. First Horizon Advisors Inc.’s holdings in Halozyme Therapeutics were worth $55,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of HALO. Parkside Financial Bank & Trust acquired a new position in shares of Halozyme Therapeutics during the fourth quarter worth approximately $64,000. Headlands Technologies LLC raised its holdings in Halozyme Therapeutics by 1,068.2% during the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 1,613 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at $196,000. EP Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter valued at about $211,000. Finally, Cetera Trust Company N.A bought a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $208,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Trading Up 0.9 %

Shares of Halozyme Therapeutics stock opened at $41.21 on Wednesday. The firm has a market cap of $5.24 billion, a PE ratio of 19.53, a P/E/G ratio of 0.47 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 1 year low of $29.85 and a 1 year high of $45.00. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. The stock has a fifty day moving average price of $40.04 and a 200-day moving average price of $37.99.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Benchmark reaffirmed a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. TD Cowen initiated coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target for the company. The Goldman Sachs Group cut their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $53.29.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at $6,519,075.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 30,000 shares of company stock worth $1,196,800 in the last quarter. Insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.